Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion

Immediately accretive transaction includes development and commercial assets including AMITIZA® (lubiprostone), a leading product in branded constipation market Mallinckrodt expects accretion to 2018 adjusted diluted earnings per share of at least $... Biopharmaceuticals, Mergers & Acquisitions Mallinckrodt, Sucampo Pharmaceuticals
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news